We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZURA icon
51
Zura Bio
ZURA
$548M
$10.4M 0.48%
1,759,295
+1,128,892
+179% +$5.38M
OKUR
52
OnKure Therapeutics
OKUR
$153M
$10.2M 0.47%
2,238,684
-196,257
-8% -$842K
MAZE
53
Maze Therapeutics
MAZE
$1.52B
$10.1M 0.46%
339,276
+289,181
+577% +$7.58M
XENE icon
54
Xenon Pharmaceuticals
XENE
$5.81B
$10.1M 0.46%
166,550
-62,349
-27% -$3.46M
TEVA icon
55
Teva Pharmaceuticals
TEVA
$42.5B
$9.41M 0.43%
277,848
+9,457
+4% +$315K
URGN icon
56
UroGen Pharma
URGN
$2.13B
$9.29M 0.43%
252,395
-143,064
-36% -$3.88M
FTH
57
Faeth Therapeutics
FTH
$874M
$9.03M 0.41%
+361,010
New +$8.35M
AMLX icon
58
Amylyx Pharmaceuticals
AMLX
$3.87B
$8.88M 0.41%
494,378
-506,226
-51% -$7.83M
DBVT
59
DBV Technologies
DBVT
$851M
$8.66M 0.4%
528,295
-484,571
-48% -$9.14M
SVRA icon
60
Savara
SVRA
$1.08B
$8.64M 0.4%
1,403,409
-61,126
-4% -$328K
PCVX icon
61
Vaxcyte
PCVX
$8.9B
$8.49M 0.39%
146,034
-113,103
-44% -$6.14M
CGON icon
62
CG Oncology
CGON
$6.59B
$8.43M 0.39%
118,664
-67,035
-36% -$4.38M
MLYS icon
63
Mineralys Therapeutics
MLYS
$2.26B
$8.06M 0.37%
298,886
+144,200
+93% +$3.96M
ASND icon
64
Ascendis Pharma A/S
ASND
$16.3B
$7.63M 0.35%
28,604
+3,590
+14% +$839K
AMAN
65
Amanat Acquisition Corp
AMAN
$104M
$7.62M 0.35%
+750,000
New +$7.57M
NRIX icon
66
Nurix Therapeutics
NRIX
$2.72B
$7.6M 0.35%
313,236
+257,166
+459% +$4.38M
BHVN icon
67
Biohaven
BHVN
$2.33B
$7.47M 0.34%
501,687
+456,910
+1,020% +$4.92M
PRME icon
68
Prime Medicine
PRME
$655M
$7.37M 0.34%
1,997,552
+24,270
+1% +$80.6K
PCSC
69
DELISTED
Perceptive Capital Solutions
PCSC
$7.34M 0.34%
674,695
+175,114
+35% +$1.95M
IRD
70
Opus Genetics
IRD
$307M
$7.33M 0.34%
1,783,781
-65,223
-4% -$304K
LXEO icon
71
Lexeo Therapeutics
LXEO
$399M
$7.29M 0.33%
1,565,950
+98,600
+7% +$533K
DMRA
72
Damora Therapeutics
DMRA
$1.79B
$7.28M 0.33%
280,000
+1,000
+0.4% +$24.2K
REPL icon
73
Replimune Group
REPL
$1.46B
$7.26M 0.33%
655,784
-927,203
-59% -$5.67M
LONA
74
LeonaBio Inc
LONA
$74.8M
$7.14M 0.33%
777,100
+49,619
+7% +$462K
KRRO icon
75
Korro Bio
KRRO
$190M
$7.12M 0.33%
540,054
– –
1 2
3
4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.